NMRA vs. ADMA, FDMT, TARS, VIR, SRRK, CGEM, INBX, FUSN, AUTL, and TWST
Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include ADMA Biologics (ADMA), 4D Molecular Therapeutics (FDMT), Tarsus Pharmaceuticals (TARS), Vir Biotechnology (VIR), Scholar Rock (SRRK), Cullinan Oncology (CGEM), Inhibrx (INBX), Fusion Pharmaceuticals (FUSN), Autolus Therapeutics (AUTL), and Twist Bioscience (TWST). These companies are all part of the "biological products, except diagnostic" industry.
Neumora Therapeutics (NASDAQ:NMRA) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.
ADMA Biologics has higher revenue and earnings than Neumora Therapeutics.
Neumora Therapeutics has a net margin of 0.00% compared to ADMA Biologics' net margin of -10.94%. ADMA Biologics' return on equity of 0.49% beat Neumora Therapeutics' return on equity.
47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Neumora Therapeutics presently has a consensus target price of $22.57, suggesting a potential upside of 130.32%. ADMA Biologics has a consensus target price of $7.88, suggesting a potential upside of 13.64%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than ADMA Biologics.
ADMA Biologics received 391 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 71.48% of users gave ADMA Biologics an outperform vote.
In the previous week, ADMA Biologics had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 9 mentions for ADMA Biologics and 6 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.39 beat ADMA Biologics' score of 0.05 indicating that Neumora Therapeutics is being referred to more favorably in the media.
Summary
ADMA Biologics beats Neumora Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Neumora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neumora Therapeutics Competitors List
Related Companies and Tools
